Law360 (April 8, 2009, 12:00 AM EDT) -- Genentech Inc. is withdrawing its psoriasis drug Raptiva from the U.S. market following reports that three patients using the drug died of progressive multifocal leukoencephalopathy, a rare central nervous system infection.
Genentech said Wednesday that doctors should immediately stop prescribing the drug, and should contact patients currently taking it to assess alternative treatments. Genentech will stop selling the drug on June 8.
The company estimates that about 2,000 patients in the U.S. are currently taking Raptiva for chronic psoriasis.
"Our decision to remove Raptiva from the market reflects Genentech's commitment to patient safety," said Hal Barron, Genentech's senior vice president for...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!